全球PD-1/PD-L1单克隆抗体市场竞争格局

目的:从产品开发角度分析PD-1/PD-L1单克隆抗体的发展现状和未来趋势。方法:检索科睿唯安(Clarivate Analytics)的Cortellis数据库的数据,利用定量分析法和对比分析法对检索结果进行分析。结果:目前已有5种PD-1/PD-L1单克隆抗体上市、4种PD-1/PD-L1单克隆抗体处于预注册及6种PD-1/PD-L1单克隆抗体处于临床Ⅲ期,未来市场上的PD-1/PD-L1单克隆抗体将呈现快速增长趋势。此外,PD-1/PD-L1单克隆抗体的商业交易也越来越多,目前共发生包括药物开发及商业化许可、专利资产出售及早期药物研发合作等10余起交易,其中药物开发及商业化许可是最主要的交易模式。结论:虽然PD-1/PD-L1单克隆抗体市场尚处于起步阶段,但随着未来技术的不断发展改进,相信未来有更多的PD-1/PD-L1单克隆抗体上市,为癌症及其他疾病的治疗提供新的契机。

Market Competition Pattern of Global PD-1/PD-L1 Monoclonal Antibody

Objective:To analyze the development status and trend of PD-1/PD-L1 monoclonal antibody in the sense of product manufacturing.Methods:Based on the Cortellis database of Clarivate analytics, the searching results with utilizing quantitative analysis and comparative analysis methods were analyzed.Results:Currently, five PD-1/PD-L1 monoclonal antibodies have been launched into markets, another three PD-1/PD-L1 monoclonal antibodies are at registration phase and four at phase III clinical trial. In addition, business deals related to PD-1/PD-L1 monoclonal antibody are increasing in recent years, including more than 10 deals so far, ranging from drug development, commercial license, and patent assets sales to drug R&D cooperation in early phase. As for China, several PD-1/PD-L1 monoclonal antibodies are at clinical stage, and a bright prospect can be expected for Chinese oligonucleotide therapeutic product markets.Conclusion:Although PD-1/PD-L1 monoclonal antibody market still at its preliminary stage, however, with the continuous development and improvement of future technology, it is believed that more PD-1/PD-L1 monoclonal antibody will be launched in the future, providing a new opportunity for the treatment of cancer and other diseases.